Elutia Reports Q1 Sales Growth to $3.1M, Gross Margin Rises to 58%, Net Loss Widens
Elutia reported Q1 net sales of $3.1 million, up 6% year-over-year, with gross margins rising to 58% (67% adjusted) even as SimpliDerm revenue fell to $2.1 million and net loss widened to $7.5 million. The company closed with $36.5 million cash and escrow, advancing its NXT-41x FDA submission.
1. Q1 Financial Results
Elutia reported Q1 net sales of $3.1 million, up 6% year-over-year as cardiovascular revenue rose to $1.0 million from $0.3 million while SimpliDerm fell to $2.1 million. GAAP gross margin improved to 58% (67% adjusted), net loss widened to $7.5 million and adjusted EBITDA loss reached $4.4 million on $8.2 million operating expenses, ending with $36.5 million in cash and escrow.
2. Strategic Developments
The company advanced its NXT-41x program through substantive FDA interactions, increasing confidence in a first-half 2027 clearance, and brought its automated manufacturing platform online to target over 80% gross margin at scale. Direct surgeon engagement highlighted a $1.5 billion U.S. breast reconstruction opportunity driven by high post-operative infection rates.
3. Divestiture Process and Outlook
Elutia is pursuing divestiture of its SimpliDerm and cardiovascular product lines, potentially reshaping future revenue streams and strategic focus. The prior sale of its EluPro product for $88 million supports its commercialization approach, with management anticipating that divestiture outcomes and NXT-41x progress will extend cash runway and underpin long-term growth.